prtgb Antibody

What is Protogenin (Prtg) and what makes it significant for developmental research?

Protogenin (Prtg) is a transmembrane protein belonging to the immunoglobulin superfamily (IgSF). It comprises a signal peptide (SP), 4 immunoglobulin (Ig) domains, 5 fibronectin (FN)-type III repeats, a single transmembrane domain (TM), and a cytoplasmic domain (CD) . Prtg is particularly significant in developmental biology because it demonstrates high expression during early embryonic stages and markedly decreases in later developmental stages. Research indicates it plays crucial roles in neural tube development, tooth morphogenesis, and potentially cognitive development . Recent studies have also identified Prtg-positive stem cells as potentially initiating Group 3 medulloblastoma, making it an important target for both developmental studies and cancer research .

What is the expression pattern of Prtg during embryonic development?

Prtg exhibits a distinct temporal and spatial expression pattern during embryonic development:

• Highest expression occurs at early-middle stages of embryogenesis (approximately E10.5 in mice)

• Expression dramatically decreases after E12.0 in mouse embryos

• By E18.0, only faint expression remains in specific tissues

• Tissue distribution includes:

  • Neural tube and developing central nervous system

  • First branchial arch and mandibular mesenchyme

  • Oral epithelial layer

  • Developing tooth germ (enamel organ and dental papilla)

  • Retina and lens

The protein demonstrates strong expression in both epithelial and mesenchymal cells in early development with progressive restriction and reduction in later stages . In adults, weak expression persists primarily in the central nervous system .

How should Prtg antibodies be stored and handled for optimal performance?

For optimal antibody performance when working with Prtg antibodies:

• Store in manual defrost freezer and avoid repeated freeze-thaw cycles

• Maintain at -20 to -70°C for up to 12 months from date of receipt (as supplied)

• After reconstitution, store at 2 to 8°C under sterile conditions for up to 1 month

• For longer storage after reconstitution, maintain at -20 to -70°C under sterile conditions for up to 6 months

Proper handling includes careful reconstitution following manufacturer's protocols, working with pre-chilled equipment when preparing dilutions, and maintaining sterile conditions during all manipulations to preserve antibody integrity and specificity .

What immunohistochemical methods are most effective for detecting Prtg in tissue sections?

Based on published protocols, the following method has proven effective for Prtg detection:

Immunofluorescence protocol for frozen sections:

• Use immersion-fixed frozen sections (optimal for preserving Prtg epitopes)

• Apply primary anti-Prtg antibody at 10 μg/mL concentration

• Incubate overnight at 4°C to maximize specific binding

• Detect using fluorophore-conjugated secondary antibodies (e.g., NorthernLights™ 493-conjugated Anti-Sheep IgG)

• Counterstain nuclei with DAPI

• Perform confocal microscopy for optimal visualization

In embryonic tissues, Prtg protein typically shows a distinctive punctate appearance surrounding cells, consistent with its membrane localization . For paraffin sections, antigen retrieval steps may be necessary, though this can potentially affect epitope integrity.

How can researchers distinguish between specific and non-specific binding when using Prtg antibodies?

To ensure specificity and minimize false positives when working with Prtg antibodies:

• Essential controls:

  • Negative controls: Omit primary antibody while maintaining all other conditions

  • Isotype controls: Use non-specific antibodies of the same isotype

  • Blocking controls: Pre-incubate antibody with recombinant Prtg protein

• Validation approaches:

  • Comparative analysis with mRNA expression (in situ hybridization)

  • Confirmation with multiple antibodies targeting different Prtg epitopes

  • Knockout/knockdown validation where Prtg expression is inhibited

  • Western blot confirmation of expected molecular weight (~180 kDa native, ~130 kDa after deglycosylation)

• Technical considerations:

  • Note that Prtg undergoes extensive post-translational modifications, particularly N-glycosylation

  • Treatment with N-glycosidase F can confirm specificity by demonstrating appropriate size reduction

  • Evaluate cellular localization pattern (should be primarily membranous)

What are the optimal experimental conditions for using Prtg antibodies in Western blotting?

For Western blot analysis of Prtg, researchers should consider:

Sample preparation:

• Process tissues quickly to prevent protein degradation

• Use appropriate lysis buffers containing protease inhibitors

• Include phosphatase inhibitors if investigating phosphorylation states

Electrophoresis considerations:

• Expected molecular weight: ~180 kDa for glycosylated protein

• After N-glycosidase F treatment: reduced size but still larger than 130 kDa (suggesting O-glycosylation and phosphorylation)

• Use 6-8% gels for better resolution of high molecular weight proteins

• Extended transfer times may be necessary for complete transfer

Detection optimization:

• Polyclonal antibodies have shown better sensitivity in detecting native Prtg

• Blocking with 5% non-fat milk or BSA depending on antibody specifications

• Overnight primary antibody incubation at 4°C may improve signal

• Consider enhanced chemiluminescence detection systems for optimal sensitivity

Controls and verification:

• Include positive control (tissue known to express Prtg, such as E10.5 mouse mandible)

• Implement negative controls (tissue with minimal Prtg expression)

• Consider deglycosylation experiments to confirm identity

How can Prtg antibodies be applied to investigate the relationship between Prtg and cognitive function?

Recent research has established connections between Prtg and cognitive function through the following approaches:

• Proteomics and cognitive correlation studies:

  • Prtg has been identified among neurology-related protein biomarkers associated with general fluid cognitive ability in older individuals

  • Ectodysplasin A2 receptor (EDA2R), which showed the strongest association with cognitive ability in the Lothian Birth Cohort 1936, appears to have functional relationships with Prtg

  • Lower Prtg levels were associated with higher cognitive ability, suggesting it may function as a negative regulator in cognitive processes

• Methodological approaches for investigation:

  • Measure Prtg levels in plasma samples using high-throughput proteomics platforms

  • Correlate Prtg levels with standardized cognitive assessments

  • Analyze relationships between Prtg expression and brain structural variables (total brain volume, grey matter and white matter volumes)

  • Investigate mediation effects of brain structural variables on Prtg-cognition relationships

• Technical considerations:

  • Age-matching is critical as Prtg associations with cognitive function appear age-dependent

  • Effect sizes differ between cohorts, requiring careful methodological controls

  • Sample collection method (tube type) may affect results

What approaches can be used to target Prtg-positive cells in developmental and cancer research models?

Based on recent advances, several approaches have been developed for targeting Prtg-positive cells:

• Genetic targeting approaches:

  • Diphtheria toxin system for selective ablation of Prtg-expressing cells

  • Chimeric antigen receptor (CAR) T cells directed against Prtg-positive cells (shown effective against Group 3 medulloblastoma)

• Molecular inhibition strategies:

  • Antisense-phosphorothioated-oligodeoxynucleotide (AS-S-ODN) for Prtg mRNA inhibition in developmental studies

  • Targeted molecular approaches focusing on downstream pathways (e.g., BMP-4, which is downregulated following Prtg inhibition)

• Therapeutic targeting considerations:

  • Focus on the PRTG-high compartment in tumors

  • Consider targeting the perivascular niche where Prtg-positive stem cells reside

  • Monitor effects on both target cells and associated tissues

How does microRNA regulation of Prtg affect its developmental functions?

Research has identified significant microRNA-mediated regulation of Prtg:

• Key regulatory microRNAs:

  • Prtg is directly regulated by let-7, miR-9, and miR-125 (collectively termed LP-miRNAs)

  • These microRNAs target specific sites in the 3' UTR of Prtg mRNA

• Experimental evidence:

  • Luciferase reporter assays with Prtg 3' UTR constructs demonstrate direct regulation

  • Mutation of miRNA consensus sites in the 3' UTR abolishes regulation

  • Dicer conditional knockout mice show increased Prtg expression

  • Rescue experiments with miRNA mimics reduce Prtg expression in Dicer CKO mice

• Developmental significance:

  • microRNA regulation creates temporal control of Prtg expression

  • This regulation appears crucial for developmental timing in retinal development

  • Similar microRNA regulatory mechanisms may operate in other developmental contexts

How should researchers interpret differences in Prtg antibody binding across different experimental systems?

When encountering variability in Prtg antibody binding across experimental systems, consider:

• Post-translational modification differences:

  • Prtg undergoes extensive N-glycosylation affecting its molecular weight (~180 kDa observed vs. ~130 kDa predicted)

  • Additional O-glycosylation and phosphorylation may occur

  • These modifications can vary between tissue types and developmental stages

  • Different cell culture systems may produce Prtg with varying glycosylation patterns

• Expression level considerations:

  • Prtg expression decreases dramatically during development (e.g., E12.0 mouse mandible shows <5% of the expression level at E10.5)

  • Expression is primarily restricted to early embryonic stages with minimal expression in adult tissues

  • Temporal dynamics must be accounted for when comparing results across developmental timepoints

• Methodological factors:

  • Different antibody clones may recognize distinct epitopes

  • Sample preparation methods can affect epitope accessibility

  • Fixation protocols may differentially preserve Prtg structure

  • Buffer compositions and incubation conditions influence binding efficiency

What are the relationships between Prtg and other developmentally regulated proteins?

Prtg interactions with other developmental proteins include:

• Relationship with BMP-4:

  • Inhibition of Prtg using AS-S-ODN significantly decreases BMP-4 expression

  • This suggests Prtg may function upstream of BMP-4 in developmental signaling pathways

  • The relationship appears functionally significant for tooth germ development

• Structural similarities with DCC subfamily:

  • Prtg shares structural characteristics with DCC, Neogenin, Punc, and Nope

  • These proteins collectively form the DEAL subfamily within the immunoglobulin superfamily

  • This suggests potential functional similarities or overlapping roles

• Relationship with Lin28b:

  • Both Prtg and Lin28b are regulated by the same microRNAs (let-7, miR-9, and miR-125)

  • They show similar temporal expression patterns during development

  • This coordinated regulation suggests they may function in related developmental pathways

What unique considerations should researchers address when using Prtg antibodies for detecting cancer stem cell populations?

When investigating Prtg-positive cancer stem cells, particularly in medulloblastoma research:

• Phenotypic characterization:

  • Prtg-positive stem cells in Group 3 medulloblastoma exhibit MYC^high NESTIN^low characteristics

  • They preferentially localize to perivascular niches, similar to their developmental counterparts

  • Double-staining with MYC and NESTIN can help identify the relevant population

• Microenvironmental considerations:

  • Consider co-staining for endothelial markers to identify association with vasculature

  • The human-specific interposed vascular plexus is particularly relevant

  • Endothelial cells adopt an immature phenotype when co-cultured with Prtg-positive tumor cells

• Technical approaches:

  • Flow cytometry protocols should be optimized for membrane proteins

  • Single-cell approaches may provide insights into heterogeneity

  • Spatial transcriptomics techniques can help understand niche interactions

  • Combination with functional assays (e.g., tumor initiation) can validate stem cell properties

• Therapeutic targeting considerations:

  • CAR-T cells and diphtheria toxin-based approaches have shown efficacy

  • Monitoring of the Prtg^high compartment can serve as a measure of treatment efficacy

  • Combined targeting of both Prtg-positive cells and their niche may be necessary

How do different sample collection and storage conditions affect the reliability of Prtg protein detection?

To ensure reliable Prtg detection across different experimental settings:

• Sample collection timing:

  • Process samples quickly to prevent protein degradation

  • Consider that Prtg expression is highly dynamic during development

  • Time-course experiments should maintain consistent collection protocols

• Processing considerations:

  • Serum samples should be processed within 24 hours of collection

  • Avoid freeze-thaw cycles (use single-use aliquots)

  • Store at −80°C for long-term preservation

• Methodological standardization:

  • Different collection tubes (citrate vs. EDTA) may affect protein detection

  • Standardize collection protocols when comparing across cohorts

  • Document any deviations in collection or processing methods

  • Consider that effect sizes may differ between populations even with identical protocols

How does Prtg expression compare between embryonic and adult tissues?

Prtg demonstrates distinct expression differences between embryonic and adult tissues:

This dramatic temporal regulation suggests Prtg functions primarily in early developmental processes with minimal roles in adult tissues outside the central nervous system .

What methodological approaches can resolve contradictory findings in Prtg expression studies?

When faced with contradictory findings regarding Prtg expression:

• Multi-method validation:

  • Combine protein detection (IHC, Western blot) with mRNA analysis (ISH, RT-PCR)

  • Quantitative approaches (qPCR, ELISA) provide more precise measurement

  • Single-cell techniques can reveal heterogeneity masked in bulk analysis

• Temporal resolution:

  • High-resolution time-course studies can capture rapid expression changes

  • Prtg expression in mouse mandible decreases to <40% within 24 hours and <15% within 48 hours in culture

  • Precise developmental staging is critical for comparative studies

• Technical standardization:

  • Document antibody clone, concentration, and incubation conditions

  • Consider epitope accessibility in different preparation methods

  • Standardize image acquisition and quantification parameters

  • Include appropriate positive and negative controls

• Cross-validation strategies:

  • Use multiple antibodies targeting different epitopes

  • Implement genetic approaches (knockdown/knockout) as validation

  • Consider species differences when comparing across model systems

By implementing these approaches, researchers can better reconcile apparently contradictory findings and establish more consistent understanding of Prtg expression patterns.

How can Prtg antibodies contribute to understanding the role of proteomics in predicting cognitive decline?

Recent research has established connections between neurological proteins and cognitive function:

• Proteomic biomarker profiles:

  • Neurology-related protein biomarkers, including Prtg, show associations with general fluid cognitive ability

  • These associations appear particularly relevant in older individuals

  • Lower levels of certain proteins, including Prtg, correlate with higher cognitive ability

• Methodological approaches:

  • Multi-protein panels outperform single protein measurements

  • Principal component analysis of protein measurements can identify meaningful patterns

  • Age-matched cohorts are essential for valid comparisons

  • Longitudinal studies can track protein levels and cognitive changes over time

• Clinical implications:

  • Proteomic signatures may predict future cognitive decline

  • Blood-based biomarkers offer accessible tools for monitoring disease activity

  • Integration with neuroimaging data enhances predictive value

• Technical considerations:

  • Standardized collection and processing protocols are critical

  • High-throughput platforms like Proximity Extension Assay on the Olink platform enable efficient analysis

  • Custom multiple sclerosis disease activity (MSDA) assay panels demonstrate utility in neurodegenerative contexts

What advanced techniques can improve detection sensitivity for low-abundance Prtg in adult tissues?

For detecting low-abundance Prtg in adult tissues, consider these advanced approaches:

• Enhanced signal amplification:

  • Tyramide signal amplification (TSA) can increase sensitivity 10-100 fold

  • Polymer-based detection systems improve signal without increasing background

  • Quantum dot conjugated antibodies provide superior signal-to-noise ratio

• Sample enrichment strategies:

  • Laser capture microdissection to isolate specific cell populations

  • Immunoprecipitation before Western blotting

  • Proximity ligation assay for detecting protein interactions in situ

• Advanced imaging techniques:

  • Super-resolution microscopy to detect subcellular localization

  • Multispectral imaging to distinguish signal from tissue autofluorescence

  • Digital pathology with automated quantification for objective measurement

• Molecular amplification:

  • In situ PCR for detecting low-abundance transcripts

  • RNAscope technology for single-molecule RNA detection

  • Digital droplet PCR for absolute quantification of transcript numbers

These approaches can significantly improve detection sensitivity while maintaining specificity, enabling more accurate characterization of low-abundance Prtg in adult tissues.

How can researchers address common challenges when using Prtg antibodies in immunohistochemistry?

Common challenges and solutions when using Prtg antibodies include:

• High background staining:

  • Increase blocking time/concentration (5% BSA or 10% normal serum)

  • Optimize antibody dilution (perform titration experiments)

  • Include 0.1-0.3% Triton X-100 for better antibody penetration

  • Reduce secondary antibody concentration

  • Perform additional washing steps with 0.1% Tween-20

• Weak or absent signal:

  • Verify tissue expression timing (Prtg expression is dramatically reduced after E12.0 in mouse)

  • Try antigen retrieval methods for fixed tissues

  • Increase primary antibody concentration

  • Extend incubation time (overnight at 4°C)

  • Use signal amplification systems

• Non-specific binding:

  • Pre-absorb antibody with related proteins

  • Include additional blocking agents (0.1% gelatin, 0.5% Tween-20)

  • Use more stringent washing conditions

  • Validate with appropriate controls (including genetic knockdown)

• Inconsistent staining:

  • Standardize tissue fixation time and conditions

  • Process all samples simultaneously

  • Use automated staining platforms if available

  • Include positive control tissues in each experiment

What considerations are important when developing quantitative assays for Prtg expression?

For developing reliable quantitative assays for Prtg:

• Reference standard selection:

  • Recombinant Prtg protein with defined concentration

  • Well-characterized positive control tissue (e.g., E10.5 mouse mandible)

  • Internal reference genes/proteins with stable expression

• Assay validation parameters:

  • Determine linear range of detection

  • Establish lower limit of quantification

  • Document intra- and inter-assay variability

  • Perform spike-and-recovery experiments

• Normalization strategies:

  • Total protein normalization (BCA, Bradford assays)

  • Housekeeping proteins (carefully selected for stability)

  • Potential for ratiometric analysis with related proteins

• Technical considerations:

  • Account for post-translational modifications

  • Consider native vs. denatured detection systems

  • Establish standardized sample collection and processing

  • Document freeze-thaw stability